MBF Therapeutics Names Ronald Cravens, MS, DVM, Executive Vice President of Business Development
Ambler, PA – MBF Therapeutics, the leader in the development of DNA-based immunotherapeutic checkpoint inhibitor vaccines for the animal health market, has added Dr. Ronald Cravens to its senior management team as executive vice president of business development.
Dr. Cravens brings to MBF Therapeutics a wealth of global business management and product development experience from his leadership roles in the animal health and life sciences industry. Among his most recent senior executive positions, Dr. Cravens led the development of new products and significantly grew sales as president for 12 years of Amlan International—the animal health nutrition division of Oil-Dri Corporation of America. Other animal health companies where Dr. Cravens led and executed successful business and product development strategies include Novartis Animal Vaccines, Inc. (President and CEO), Pfizer Animal Health (Director/Senior Marketing Manager, Global Biologicals), and SmithKline Beecham Animal Health (Director, Worldwide Strategic Product Development).
Dr. Cravens received his MS in environmental health and DVM from Colorado State University in Fort Collins, Colorado.
“We’re pleased to add Ron to our senior management team at this exciting stage of our business growth,” says Thomas Tillett, CEO of MBF Therapeutics. “We’re confident that he will be instrumental in helping MBF Therapeutics move research and product development forward with our innovative gene-based, T-cell directed vaccine platform technology.”
“I’m excited to join the MBF Therapeutics team,” says Dr. Cravens. “I see great potential for this company’s checkpoint inhibitor immunotherapy technology in the treatment of cancer and the prevention of infectious diseases for both companion animals and livestock. I predict it’s going to be a game changer in the animal health industry.”
About MBF Therapeutics: MBFT (www.mbftherapeutics.com) MBFT is a clinical-stage animal health company developing and commercializing proprietary checkpoint inhibitor immunotherapy technology for cancer and infectious diseases. T-cell activation precisely targets selected antigens associated with cancer cells or infectious pathogens while preventing T-cell exhaustion, thus, yielding a durable cell-mediated immunity. Exclusively licensed from the Wistar Institute in Philadelphia, PA, and combined with a proprietary nonviral delivery system, this is a platform technology from which multiple innovative products can be developed for veterinary use where cellular antigens are well defined.